25-Hydroxyvitamin D3-1 alpha-hydroxylase (25(OH)D3-1 alpha-hydroxylase), the key enzyme of 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) production, is expressed in monocyte-derived macrophages (MACs). Here we show for the first time constitutive expression of 25(OH)D3-1 alpha-hydroxylase in monocyte-derived dendritic cells (DCs), which was increased after stimulation with lipopolysaccharide (LPS). Accordingly, DCs showed low constitutive production of 1,25(OH)2D3, but activation by LPS increased 1,25(OH)2D3 synthesis. In addition, 25(OH)D3-1 alpha-hydroxylase expression was found in blood DCs but not in CD34+-derived DCs. Next we analyzed the functional consequences of these results. Addition of 1,25(OH)2D3 at concentrations comparable with those produced by DCs inhibited the allostimulatory potential of DCs during the early phase of DC differentiation. However, terminal differentiation decreased the responsiveness of DCs to 1,25(OH)2D3. In conclusion, DCs are able to produce 1,25(OH)2D3 especially following stimulation with LPS. Terminal maturation renders DCs unresponsive to the effects of 1,25(OH)2D3, but those cells are able to suppress the differentiation of their own precursor cells in a paracrine way through the production of 1,25(OH)2D3.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2002-11-3521 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The conversion of circulating 25-hydroxyvitamin D3 (25OHD3) to its active metabolite 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] in the renal tubule mitochondrion by the enzyme 25OHD3-1 alpha-hydroxylase is closely regulated in vivo according to the physiological need for calcium and phosphorus. The mechanism by which this regulation is achieved at the cellular level has not been clarified, although a number of lines of evidence suggest that calcium ions (Ca2+) are involved. This study was designed to determine whether calmodulin, the ubiquitous cell protein that binds and mediates many of the regulatory functions of Ca2+, plays a role in the regulation of renal vitamin D metabolism.
View Article and Find Full Text PDFEffect of dexamethasone on 25-hydroxyvitamin D3 metabolism by chick kidney cell cultures.
Endocrinology
March 1986
The ability of dexamethasone to alter the metabolism of [3H]25-hydroxyvitamin D3 ([3H]25OHD3) metabolism by primary cultures of chick kidney cells was tested. Dexamethasone, present for 24 or 48 h at 10(-8)-10(-6) M, decreased production of [3H]1,25-dihydroxyvitamin D3 to approximately 60% of control levels. If cultures were pretreated with 1,25-dihydroxyvitamin D3 to reduce 25OHD3-1-hydroxylase activity and induce 25OHD3-24-hydroxylase activity, no effect of dexamethasone on either of the enzymes was observed.
View Article and Find Full Text PDFIn 1974, a 2-year-old boy was diagnosed as having X-linked hypophosphataemic rickets (XLH) because of severe rickets and hypophosphataemia. The vitamin D metabolite concentrations, blood and urine chemistry and renal 25-hydroxyvitamin D3 (25OHD3)-1 alpha-hydroxylase were measured in 1982 (about 2 weeks after withdrawal of medication). 1 alpha-hydroxylase was 392 pg/mg tissue/20 min in the patient, which was high compared with aged-matched controls (69.
View Article and Find Full Text PDFPrevious studies in vitamin D deficient animals showing that acidosis may impair the production of 1,25(OH)2D3 are in conflict with studies in humans which have not shown convincing disturbances of 25OHD3 metabolism during acidosis. We have investigated the effect on renal 25OHD3 1- and 24-hydroxylase of acid loading for periods of 24 hr to 21 days. Acid loading resulted in immediate and sustained decrements in arterial pH and bicarbonate and increments in blood-ionized calcium.
View Article and Find Full Text PDFLong term 25-hydroxyvitamin D3 therapy in postmenopausal osteoporosis: demonstration of responsive and nonresponsive subgroups.
J Clin Endocrinol Metab
February 1983
Previous studies from our laboratory have demonstrated that 25-hydroxyvitamin D3 (25OHD3) therapy is effective in raising the impaired intestinal calcium absorption (alpha) associated with postmenopausal osteoporosis. In the present study we have assessed the effects of long term 25-OHD3 therapy (50 micrograms/day; mean treatment period, 1.3 yr) in 12 women with postmenopausal osteoporosis (mean age, 62.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!